No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IART240517P40000
- 10.70
- 0.000.00%
15min DelayTrading Apr 19 11:47 ET
0.00High0.00Low
0.00Open10.70Pre Close0 Volume0 Open Interest40.00Strike Price0.00Turnover252.48%IV0.34%PremiumMay 17, 2024Expiry Date13.69Intrinsic Value100Multiplier4DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.9001Delta0.0234Gamma1.93Leverage Ratio-0.1300Theta-0.0038Rho-1.74Eff Leverage0.0053Vega
Intraday
- 5D
- 1D
News
A Glimpse Into The Expert Outlook On Integra Lifesciences Through 8 Analysts
Analysts' ratings for Integra Lifesciences (NASDAQ:IART) over the last quarter vary from bullish to bearish, as provided by 8 analysts.The table below summarizes their recent ratings, showcasing the e
Integra LifeSciences Price Target Cut to $40.00/Share From $49.00 by JMP Securities
Integra LifeSciences Price Target Cut to $40.00/Share From $49.00 by JMP Securities
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
Integra LifeSciences Holdings Corporation IART delivered adjusted earnings per share (EPS) of 55 cents in the first quarter of 2024, down 25.7% year over year.
Oppenheimer Cuts Integra to Perform, Cites Boston Plant Delays
Integra LifeSciences Cut to Equal-Weight From Overweight by Wells Fargo
Integra LifeSciences Cut to Equal-Weight From Overweight by Wells Fargo
Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25
Wells Fargo analyst Vik Chopra downgrades Integra Lifesciences (NASDAQ:IART) from Overweight to Equal-Weight and lowers the price target from $45 to $25.
Comments
EPS growth doesn't align with share price, indicating it may not reflect business performance or growth expectations may have been high. Integra LifeSciences Holdings' performance led to a 3% annual loss for shareholders over five years. Investors should note 3 warning signs.
While Shareholders of Integra LifeSciences Holdings (NASDAQ:IART) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually GrownInsider transactions suggest a positive outlook for Integra LifeSciences Holdings, with insiders net buying the stock. The level of insider ownership indicates a reasonable degree of alignment with shareholder interests.
1
Integra LifeSciences Holdings trades at a low price, suggesting a buying opportunity. Higher cash flow is expected, potentially boosting share valuation. The positive outlook seems not fully factored into the share price, indicating it's not too late to buy IART.
Analysts insist that Integra LifeSciences' robust future growth justifies its high P/E, negating any expectations of a significant share price drop due to low odds of earnings deterioration.
The Acclarent acquisition provides Integra LifeSciences the chance to scale and seize leadership in the ENT device segment, enriching its innovative portfolio and providing shareholder value. In tandem with Integra's neurosurgery segment, it signifies a strategic move that will enhance innovation across ENT and other CSS technologies.
Read more